Drug Profile
Timtraxanib - Avixgen
Alternative Names: AVI-3207Latest Information Update: 30 Jun 2023
Price :
$50
*
At a glance
- Originator Avixgen
- Developer Avixgen; Bixzen; Ebixen
- Class Eye disorder therapies; Peptides
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Age-related macular degeneration
- No development reported Diabetic macular oedema
Most Recent Events
- 25 May 2023 Timtraxanib is still in phase I trials for Age-related-acular-degeneration in South Korea (Avixgen pipeline, May 2023)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in South Korea
- 28 Oct 2021 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in South Korea (Intravitreous, Injection)